Pharmacological characterization of AR-M1000390 at human delta opioid receptors

Life Sciences

Volumn 73, Issue 13, 2003, Pages 1691-1704

  Marie, Nicolas ^a   Landemore, Gérard ^a   Debout, Claire ^a   Jauzac, Philippe ^a   Allouche, Stéphane ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Confocal laser microscopy; Desensitization; Human delta opioid receptors; Internalization; SK N BE cells

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ANTIBODY; AR M1000390; CLATHRIN; CYCLIC AMP; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; FORSKOLIN; SUCROSE;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CORRELATION ANALYSIS; DESENSITIZATION; DOWN REGULATION; DRUG POTENCY; DRUG SYNTHESIS; ENDOCYTOSIS; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; TUMOR CELL LINE;

EID: 0038784444     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00489-2     Document Type: Article

References (29)

1. Allouche S., Polastron J., Jauzac P. The delta-opioid receptor regulates activity of ryanodine receptors in the human neuroblastoma cell line SK-N-BE. Journal of Neurochemistry. 67:1996;2461-2470.
2. Allouche S., Roussel M., Marie N., Jauzac P. Differential desensitization of human delta-opioid receptors by peptide and alkaloid agonists. European Journal of Pharmacology. 371:1999;235-240.
3. Allouche S., Hasbi A., Ferey V., Sola B., Jauzac P., Polastron J. Pharmacological delta1- and delta2-opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. Biochemical Pharmacology. 59:2000;915-925.
4. Arden J.R., Segredo V., Wang Z., Lameh J., Sadée W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK 293 cells. Journal of Neurochemistry. 65:1995;1636-1645.
5. Bilsky E.J., Calderon S.N., Wang T., Bernstein R.N., Davis P., Hruby V.J., McNutt R.W., Rothman R.B., Rice K.C., Porreca F. SNC-80, a selective, nonpeptidic and systemically active opioid delta agonist. Journal of Pharmacology and Experimental Therapeutics. 273:1995;359-366.
6. Borgland S.L. Acute opioid receptor desensitization and tolerance: is there a link? Clinical and Experimental Pharmacology and Physiology. 28:2001;147-154.
7. 50) of an enzymatic reaction. Biochemical Pharmacology. 22:1973;3099-3102.
8. Dondio G., Ronzoni S., Petrillo P. Non-peptide δ-opioid agonists and antagonists (Part II). Expert Opinion on Therapeutic Patents. 9:1999;353-374.
9. Ferguson S.S.G. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacological Reviews. 53:2001;1-24.
10. Finn A.K., Whistler J.L. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron. 32:2001;829-839.
11. Hasbi A., Polastron J., Allouche S., Stanasila L., Massotte D., Jauzac P. Desensitization of the delta-opioid receptor correlates with its phosphorylation in SK-N-BE cells: involvement of a G protein-coupled receptor kinase. Journal of Neurochemistry. 70:1998;2129-2138.
12. Hasbi A., Allouche S., Sichel F., Stanasila L., Massotte D., Landemore G., Polastron J., Jauzac P. Internalization and recycling of δ-opioid receptor are dependent on a phosphorylation-dephosphorylation mechanism. Journal of Pharmacology and Experimental Therapeutics. 293:2000;237-247.
13. 6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 257:1991;1069-1075.
14. Kieffer B.L. Opioids: first lessons from knockout mice. Trends in Pharmacological Sciences. 20:1999;19-25.
15. Law P.-Y., Wong Y.H., Loh H.H. Molecular mechanisms and regulation of opioid receptor signaling. Annual review of pharmacology and toxicology. 40:2000;389-430.
16. Law P.Y., Maestri-El Kouhen O., Solberg J., Wang W., Erickson L.J., Loh H.H. Deltorphin II-induced a rapid desensitization of δ-opioid receptor requires both phosphorylation and internalization of the receptor. Journal of Biological Chemistry. 275:2000;32057-32065.
17. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dollé P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature. 383:1996;819-823.
18. McPherson G.A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. Journal of Pharmacological Methods. 14:1985;213-228.
19. Namir N., Polastron J., Allouche S., Hasbi A., Jauzac P. The delta-opioid receptor in SK-N-BE human neuroblastoma cell line undergoes heterologous desensitization. Journal of Neurochemistry. 68:1997;1764-1772.
20. Noble F., Cox B.M. Differential desensitization of μ- and δ-opioid receptors in selected neural pathways following chronic morphine treatment. British Journal of Pharmacology. 117:1996;161-169.
21. Polastron J., Mur M., Mazarguil H., Puget A., Meunier J.C., Jauzac P. SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors. Journal of Neurochemistry. 62:1994;898-906.
22. Quock R.M., Burkey T.H., Varga E., Hosohata Y., Hosohata K., Cowell S.M., Slate C.A., Ehlert F.J., Roeske W.R., Yamamura H.I. The δ-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacological Reviews. 51:1999;503-532.
23. Remmers A.E., Clark M.J., Xy L., Medzihradsky F. Delta opioid receptor down-regulation is independent of functional G protein yet is dependent on agonist efficacy. Journal of Pharmacology and Experimental Therapeutics. 287:1998;625-632.
24. Schug S.A., Zech D., Grond S. Adverse effects of systemic opioid analgesics. Drug Safety. 7:1992;200-213.
25. Standifer K.M., Chien C.-C., Wahlestedt C., Brown G.P., Pasternak G.W. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron. 12:1994;805-810.
26. Standifer K.M., Pasternak G.W. G proteins and opioid receptor-mediated signalling. Cellular signalling. 9:1997;237-248.
27. Wang W.W., Shahrestanifar M., Jin J., Howells R.D. Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proceedings of the National Academy of Sciences USA. 92:1995;12436-12440.
28. Wang H.Q., Kampine J.P., Tseng L.F. Antisense oligodeoxynucleotide to a δ-opioid receptor messenger RNA selectively blocks the antinociception induced by intracerebroventricularly administered δ-, but not μ-, ε- or κ-opioid receptor agonists in the mouse. Neuroscience. 75:1996;445-452.
29. Wei Z.-Y., Brown W., Takasaki B., Plobeck N., Delorme D., Zhou F., Yang H., Jones P., Gawel L., Gagnon H., Schmidt R., Yue S.-Y., Walpole C., Payza K., St-Onge S., Labarre M., Godbout C., Jakob A., Butterworth J., Kamassah A., Morin P.-E., Projean D., Ducharme J., Roberts E. N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: A novel, exceptionally selective, potent dopioid receptor agonist with oral bioavailability and its analogues. Journal of Medicinal chemistry. 43:2000;3895-3905.